Biotech RadarJobs updated

COMPANY

Inovio Pharmaceuticals

HQ: Plymouth Meeting, PA source · inovio.com ↗ · Mid-Atlantic

Clinical Phase 3

Keywords: antibody rare disease hematology cancer infectious diseases Coronavirus Infection Head and Neck Cancer Cervical Dysplasia Cervical High Grade Squamous Intraepithelial Lesion Human Papillomavirus Lassa Fever Urothelial Carcinoma Glioblastoma Respiratory Papillomatosis Middle East Respiratory Syndrome Coronavirus Severe Acute Respiratory Syndrome Coronavirus 2 COVID-19 Disease Vulvar High Grade Squamous Intraepithelial Lesion (HSIL) Vulvar Dysplasia Vulvar Intraepithelial Neoplasia VIN2 VIN3 Pre-cancerous Lesions of the Vulva Anal Neoplasm Head Neck Cancer Cervical Cancer Head and Neck Squamous Cell Cancer Hepatitis B Ebola Vaccine Breast Cancer Lung Cancer Pancreatic Cancer Ovarian Cancer ColoRectal Cancer Gastric Cancer Esophageal Cancer HepatoCellular Carcinoma Aerodigestive Precancerous Lesions and Malignancies Cervical Intraepithelial Neoplasia Prostate Cancer Papillomavirus Infections HIV-1 Infection HIV Infections INO-9012

Location: Plymouth Meeting, PA · source · Oct 13, 2026

Profile checked Oct 10, 2026

$117.5MRaised (2 yrs)31Trials (company is sponsor)

Timeline

  1. Raise Follow-on offering: $20M (total, as published), announced Jul 29, 2026. Source: SEC filing. source ↗
  2. Raise Follow-on offering: $17.5M (total, as published), announced Apr 2, 2026. Source: SEC filing. source ↗
  3. Raise Follow-on offering: $25M (total, as published), announced Nov 11, 2025. Source: SEC filing. source ↗
  4. Raise Follow-on offering: $25M (total, as published), announced Jul 2, 2025. Source: SEC filing. source ↗
  5. Raise Follow-on offering: $30M (total, as published), announced Dec 13, 2024. Source: SEC filing. source ↗
  6. Trial start Phase 1: Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy Volunteers source ↗
  7. Trial start Phase 2: Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy Volunteers source ↗
  8. Trial start Phase 1: Dose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in Ghana source ↗
  9. Trial start Phase 2/Phase 3: Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure source ↗
  10. Trial start Phase 1/Phase 2: INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP) source ↗
  11. Trial start Phase 1: Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers source ↗
  12. Trial start Phase 1: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers source ↗
  13. Trial start Phase 3: REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL) source ↗
  14. Trial start Phase 1/Phase 2: INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma source ↗
  15. Trial start Phase 1/Phase 2: INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) source ↗
  16. Trial start Phase 2: VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion ( source ↗
  17. Trial start Phase 2: Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3) source ↗
  18. Trial start Phase 3: REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL) source ↗
  19. Trial start Phase 1: Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer source ↗
  20. Trial start Phase 1: Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers source ↗
  21. Trial start I: Phase I Study of INO-1800 With or Without INO-9112 + EP in Chronic Hepatitis B Subjects source ↗
  22. Trial start Phase 1: hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse source ↗
  23. Trial start Phase 1/Phase 2: Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma source ↗
  24. Trial start Phase 1/Phase 2: A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical Cancer source ↗
  25. Trial start Phase 1: Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and Malignancies source ↗

Showing 25 of 36 dated events.

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $117.5M. Last 2 years.

Clinical trials (lead sponsor) 31

RecordTitlePhaseStatusStartPrimary completion
NCT03502785INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial CarcinomaPhase 1/Phase 2CompletedJul 24, 2018May 9, 2025 (actual)
NCT03491683INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)Phase 1/Phase 2Active, not recruitingMay 31, 2018Dec 31, 2026 (estimated)
NCT04398433INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP)Phase 1/Phase 2CompletedOct 7, 2020Dec 15, 2022 (actual)
NCT04588428Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy VolunteersPhase 2CompletedJun 21, 2021Jan 19, 2023 (actual)
NCT03721978REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)Phase 3CompletedFeb 28, 2019Aug 23, 2022 (actual)
NCT04642638Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 ExposurePhase 2/Phase 3TerminatedNov 30, 2020Sep 13, 2022 (actual)
NCT03180684Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)Phase 2CompletedAug 31, 2017Jul 23, 2020 (actual)
NCT03185013REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)Phase 3CompletedJun 28, 2017Jul 8, 2020 (actual)
NCT03499795VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2Phase 2CompletedMay 15, 2018Jun 16, 2020 (actual)
NCT04093076Dose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in GhanaPhase 1CompletedJan 27, 2021Oct 14, 2022 (actual)
NCT05430958Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy VolunteersPhase 1Withdrawn2022-102024-03 (estimated)
NCT04336410Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy VolunteersPhase 1CompletedApr 3, 2020Feb 10, 2022 (actual)
NCT00198315Medpulser Electroporation With Bleomycin Study to Treat Anterior Head and Neck Squamous Cell CarcinomaPhase 3Terminated2004-062007-06 (actual)
NCT00198328Medpulser Electroporation With Bleomycin Study to Treat Posterior Head and Neck Squamous Cell CarcinomaPhase 3Terminated2004-112007-06 (actual)
NCT02172911A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical CancerPhase 1/Phase 2CompletedJun 6, 2014Sep 7, 2017 (actual)
NCT02163057Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell CarcinomaPhase 1/Phase 2CompletedAug 13, 2014Jan 23, 2017 (actual)
NCT03805984Safety, Tolerability and Immunogenicity of INO-4500 in Healthy VolunteersPhase 1CompletedMay 9, 2019Oct 21, 2020 (actual)
NCT02431312Phase I Study of INO-1800 With or Without INO-9112 + EP in Chronic Hepatitis B SubjectsICompletedJan 12, 2015May 22, 2018 (actual)
NCT02464670Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy VolunteersPhase 1Completed2015-05May 24, 2018 (actual)
NCT02960594hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of RelapsePhase 1Completed2014-12Nov 9, 2018 (actual)
NCT02241369Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and MalignanciesPhase 1Completed2014-052018-09 (actual)
NCT01304524A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3Phase 2Completed2011-042014-05 (actual)
NCT01188850Fourth Dose of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + EP in Adult Females Previously Vaccinated With Three Doses of VGX-3100Phase 1Completed2010-072011-10 (actual)
NCT02514213Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate CancerPhase 1Completed2015-07Dec 12, 2017 (actual)
NCT00198276Study Using the MedPulser Electroporation System With Bleomycin to Treat Cutaneous and Subcutaneous CancerPhase 4Completed2004-022008-09 (actual)
NCT00198263Study Using the Medpulser Electroporation System With Bleomycin to Treat Head and Neck CancerPhase 4Completed2004-012008-09 (actual)
NCT00685412Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation for CIN 2 or 3ICompleted2008-052011-01 (actual)
NCT01403155A Follow-On Study With an H5 Influenza Vaccine for Subjects Who Participated in Study FLU-001Phase 1Completed2011-052012-08 (actual)
NCT01142362Study of VGX-3400X, H5N1 Avian Influenza Virus DNA Plasmid + Electroporation in Healthy AdultsPhase 1Completed2010-062011-11 (actual)
NCT01405885A Study of DNA Vaccine With Electroporation for the Prevention of Disease Caused by H1 and H5 Influenza VirusPhase 1Completed2011-052013-08 (actual)
NCT01082692Study of PENNVAX™-B (Gag, Pol, Env) + Electroporation in HIV-1 Infected Adult ParticipantsPhase 1Completed2011-012012-08 (actual)
Feedback